First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia
Date
2020
Type:
Article
item.page.extent
item.page.accessRights
item.contributor.advisor
ORCID:
Journal Title
Journal ISSN
Volume Title
Publisher
item.page.isbn
item.page.issn
item.page.issne
item.page.doiurl
item.page.other
item.page.references
Abstract
Introduction/objectives: An interleukin-6 inhibition strategy could be effective in
selected COVID-19 patients. The objective is to present our experience of tocilizumab
use in patients with severe COVID-19.
Methods: Observational retrospective cohort study. Hospitalized patients were
evaluated by our multidisciplinary team for eventual use of tocilizumab. Patients with
progressive ventilatory impairment and evidence of a hyperinflammatory state despite
usual treatment received tocilizumab 8 mg/kg intravenous (maximum dose 800 mg),
in addition to standard treatment. The use and time of use of mechanical ventilation
(MV), the change of the Alveolar-arterial (A-a) gradient, of the ratio of arterial oxygen
partial pressure to fractional inspired oxygen (PaO2/FiO2) and of inflammation laboratory
parameters after 72 h of tocilizumab use was evaluated.
Results: 29 patients received tocilizumab. 93.1% were men, 37.9% were obese, and
34.5% had hypertension. Of the 20 patients who were not on MV when receiving
tocilizumab, 11 required non-invasive MV, for an average of 5 days, and one of them
required intubation. A-a gradient, PaO2/FiO2, and inflammation parameters improved
significantly. A better lymphocyte count, which improved significantly after tocilizumab
use, was significantly associated with less use of MV. Five patients presented positive
culture samples after tocilizumab, three being of clinical significance. A lower lymphocyte
count was associated with having a positive culture. No other significant adverse events
were seen.
Conclusion: Our study suggests the utility and shows the safety of tocilizumab use
in COVID-19 patients who have respiratory failure and evidence of hyperinflammation.
Lymphocyte improvement was a predictor of good response.
Description
item.page.coverage.spatial
item.page.sponsorship
Citation
Valenzuela O, Ibáñez S, Poli MC, Roessler P, Aylwin M, Roizen G, Iruretagoyena M, Agar V, Donoso J, Fierro M, Montes J. First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia. Front Med (Lausanne). 2020 Nov 16;7:596916. doi: 10.3389/fmed.2020.596916.
Keywords
Tocilizumab, Covid-19, SARS-CoV 2, Lymphocyte, Mechanical ventilalion